Company intelligence / Profile preview

Praesidia Biotherapeutics

Arlington/Boston area, Massachusetts, United Statespraesidiabio.com ↗

Ownership: Private
Employees: ~75
Development stage: Preclinical

Overview

Proof-of-concept achieved in animal models for two different indications; preclinical data developed across the USA, Canada, and India. Lead programs are being advanced toward IND-enabling studies with plans to enter Phase I clinical trials soon. No published human results yet.

Therapeutic areas: OncologyRare DiseasesNeurology
Modalities: Small molecules (prodrugs)Antibody-drug conjugates (ADCs)Linker-based drug delivery systems
Industry: Biotech

Drug pipeline

2 assets

PB-001

Pre-clinical

1 more asset in the full pipeline.

Request access →

Partnerships

Collaborations with academic labs, cancer research hospitals in USA, Canada, India. Actively seeking biopharma partnerships leveraging their linker technology platform.

Beyond the preview

Go deeper on Praesidia Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Praesidia Biotherapeutics.

Explore the full profile